Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06834035 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

Study acronym: IV IgG
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv5
  2. Primary and study completion dates: Mar 6, 2026 to Mar 2027v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jun 6, 2025 to Aug 4, 2025
    • Site details revised
    v3
  4. Start date: Mar 6, 2025 to Jun 6, 2025v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study objective is to see if IV IgG treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin in conjunction with VYJUVEK treatment improves wound healing and affects the levels of C7 and HSV-1 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 and HSV-1 antibodies could improve quality of life.
Trial Details
NCT Number NCT06834035
Lead Sponsor M. Peter Marinkovich
Collaborators: Epidermolysis Bullosa Research Partnership
Conditions
(from sponsor)		 Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita, Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
Related terms Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita, Epidermolysis Bullosa Dystrophica
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov